Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 74 of the 74 references it cites were found in a registry or an index; 21 of the 52 sources its claims cite were checked for support.

Identification of a novel gene signature predicting response to first-line chemotherapy in BRCA wild-type high-grade serous ovarian cancer patients

Open access

Abstract

BACKGROUND: High-grade serous ovarian cancer (HGSOC) has poor survival rates due to a combination of diagnosis at advanced stage and disease recurrence as a result of chemotherapy resistance. In BRCA1 (Breast Cancer gene 1) - or BRCA2-wild type (BRCAwt) HGSOC patients, resistance and progressive disease occur earlier and more often than in mutated BRCA. Identification of biomarkers helpful in predicting response to first-line chemotherapy is a challenge to improve BRCAwt HGSOC management. METHODS: To identify a gene signature that can predict response to first-line chemotherapy, pre-treatment tumor biopsies from a restricted cohort of BRCAwt HGSOC patients were profiled by RNA sequencing (RNA-Seq) technology. Patients were sub-grouped according to platinum-free interval (PFI), into sensitive (PFI > 12 months) and resistant (PFI < 6 months). The gene panel identified by RNA-seq analysis was then tested by high-throughput quantitative real-time PCR (HT RT-qPCR) in a validation cohort, and statistical/bioinformatic methods were used to identify eligible markers and to explore the relevant pathway/gene network enrichments of the identified gene set. Finally, a panel of primary HGSOC cell lines was exploited to uncover cell-autonomous mechanisms of resistance. RESULTS: RNA-seq identified a 42-gene panel discriminating sensitive and resistant BRCAwt HGSOC patients and pathway analysis pointed to the immune system as a possible driver of chemotherapy response. From the extended cohort analysis of the 42 DEGs (differentially expressed genes), a statistical approach combined with the random forest classifier model generated a ten-gene signature predictive of response to first-line chemotherapy. The ten-gene signature included: CKB (Creatine kinase B), CTNNBL1 (Catenin, beta like 1), GNG11 (G protein subunit gamma 11), IGFBP7 (Insulin-like growth factor-binding protein 7), PLCG2 (Phospholipase C, gamma 2), RNF24 (Ring finger protein 24), SLC15A3 (Solute carrier family 15 member 3), TSPAN31 (Tetraspanin 31), TTI1 (TELO2 interacting protein 1) and UQCC1 (Ubiquinol-cytochrome c reductase complex assembly factor). Cytotoxicity assays, combined with gene-expression analysis in primary HGSOC cell lines, allowed to define CTNNBL1, RNF24, and TTI1 as cell-autonomous contributors to tumor resistance. CONCLUSIONS: Using machine-learning techniques we have identified a gene signature that could predict response to first-line chemotherapy in BRCAwt HGSOC patients, providing a useful tool towards personalized treatment modalities.

Overview

CoChat Summary

## TL;DR

This retrospective study in BRCA-wild-type HGSOC patients identified a 10-gene expression signature that predicted response to first-line platinum-based chemotherapy. The Random Forest model based on this signature reportedly achieved about 93% accuracy and 94% precision in the validation cohort.

## Key findings

  • In the discovery cohort, RNA-seq measured 10,807 expressed genes and identified 258 differentially expressed genes (DEGs) at adjusted P < 0.05 and |log2FC| > 1; with stricter filtering (adjusted P < 0.005 and |log2FC| > 1), 42 DEGs were retained.
  • KEGG pathway analysis of the 42 DEGs found 4 significantly enriched pathways: Fc Epsilon RI signaling (combined score 184.64; padj 0.027), Inositol phosphate metabolism (166.85; 0.027), Phosphatidylinositol signaling system (110.64; 0.033), and Chemokine signaling pathway (80.53; 0.027).
  • In the validation cohort (25 sensitive, 19 resistant), HT RT-qPCR reduced the panel to 10 genes associated with chemotherapy response: 4 downregulated (GNG11, IGFBP7, PLCG2, SLC15A3) and 6 upregulated (CKB, CTNNBL1, RNF24, TSPAN31, TTI1, UQCC1).
  • The Random Forest classifier using the 10-gene signature achieved about 93% classification accuracy and 94% precision; in primary HGSOC cell lines, CTNNBL1, RNF24, and TTI1 showed the same resistance-related trend as in patient tumors.

## Methods

  • Retrospective study of 44 BRCAwt HGSOC women treated at a single center (2014–2018); discovery cohort was 14 patients (7 sensitive, 7 resistant) and validation cohort was 44 patients total with 25 sensitive and 19 resistant in the qPCR phase.
  • Pretreatment frozen tumor biopsies were profiled by RNA-seq in the discovery cohort, then the 42-gene panel was tested by HT RT-qPCR in the validation cohort; patients were classified as sensitive (PFI > 12 months) or resistant (PFI < 6 months).
  • Main analyses included differential expression testing, KEGG/ORA pathway analysis, GeneMANIA/cBioPortal network analyses, correlation between RNA-seq and qPCR, Wilcoxon testing, and a 4-fold cross-validation Random Forest classifier.

## Limitations

  • The paper states that the study was retrospective, which makes it susceptible to bias.
  • The paper states that sample size was not large enough to detect definitive associations between biomarker expression and response to therapy.
  • Evident from the text: the study was conducted at a single tertiary-care center and the signature still needs prospective validation before clinical use.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1186/s13046-022-02265-w

Cites

74 of 74 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Fig. 1 a Volcano plot of the RNA-seq data from high grade serous ovarian cancer (HGSOC) patients (n = 14, 7 sensitive and 7 resistant). The plot reports the negative log10 of the Benjamini-Hochberg adjusted P-value against the log2 fold-change (resistant vs sensitive) of the RNA-seq expression counts. The significance level for gene regulation is set to 0.05. Each gene is a dot, highlighted in blue for down-regulated genes, red for up-regulated, and grey for not-regulated ones. b Hierarchical clustering of the top 42 DEGs (Differentially expressed genes). Hierarchical agglomerative clustering based on Euclidean distance of resistant and sensitive subjects, calculated on RNA-seq standardized raw counts, over the top-42 DEGs (RNA-seq BH-adjusted P-value <5E-03 and |log2FC| > 1). c Barplot of the KEGG enrichment analysis. Barplot showing the enrichment score (x axis) and supporting genes (labels over the bars) of the 4 enriched KEGG pathways among the 42 RNA-seq top-DEGs. Enrichment data was extracted from the output of the online tool Enrichr. d GeneMania interaction networks for the 42 DEGs. The network was spatially represented using the Cytoscape degree sorted circle layout, in which all nodes with the same numbers of links are located together around the circle. The circle is composed of the 42 query genes (except the lncRNA LOC100133985) found in our study, whereas the genes inside are the result genes identified by GeneMANIA. The colour of the line connecting the genes indicates the type of communication. Our diagram encompasses co-expression in grey lines, physical interactions in red lines, pathway in green lines. The thicknesses of the links (or edges) between the genes are proportional to the interaction strengths, whereas the node size for each gene is proportional to the rank of the gene based on its importance (or gene score) within the network
Fig. 1 a Volcano plot of the RNA-seq data from high grade serous ovarian cancer (HGSOC) patients (n = 14, 7 sensitive and 7 resistant). The plot reports the negative log10 of the Benjamini-Hochberg adjusted P-value against the log2 fold-change (resistant vs sensitive) of the RNA-seq expression counts. The significance level for gene regulation is set to 0.05. Each gene is a dot, highlighted in blue for down-regulated genes, red for up-regulated, and grey for not-regulated ones. b Hierarchical clustering of the top 42 DEGs (Differentially expressed genes). Hierarchical agglomerative clustering based on Euclidean distance of resistant and sensitive subjects, calculated on RNA-seq standardized raw counts, over the top-42 DEGs (RNA-seq BH-adjusted P-value <5E-03 and |log2FC| > 1). c Barplot of the KEGG enrichment analysis. Barplot showing the enrichment score (x axis) and supporting genes (labels over the bars) of the 4 enriched KEGG pathways among the 42 RNA-seq top-DEGs. Enrichment data was extracted from the output of the online tool Enrichr. d GeneMania interaction networks for the 42 DEGs. The network was spatially represented using the Cytoscape degree sorted circle layout, in which all nodes with the same numbers of links are located together around the circle. The circle is composed of the 42 query genes (except the lncRNA LOC100133985) found in our study, whereas the genes inside are the result genes identified by GeneMANIA. The colour of the line connecting the genes indicates the type of communication. Our diagram encompasses co-expression in grey lines, physical interactions in red lines, pathway in green lines. The thicknesses of the links (or edges) between the genes are proportional to the interaction strengths, whereas the node size for each gene is proportional to the rank of the gene based on its importance (or gene score) within the networkCC BY · PubMed Central
Fig. 2 a High-throughput RT-qPCR/RNA-seq correlation over the top-42 DEGs. Simple linear regression (95% confidence interval in grey) was performed for resistant (triangles) and sensitive (circles) subjects, respectively. Pearson correlation is estimated as regression curve slope. Each regression also reports 95% confidence intervals of the estimates (95% CI) and corresponding P-values. b Volcano plot of the HT RT-qPCR data. The plot reports the negative log10 of the Benjamini-Hochberg adjusted P value against the log2 fold-change (resistant vs. sensitive). The significance level for gene regulation is set to 0.05. Each gene is a dot, highlighted in blue for down-regulated genes, red for up-regulated, and grey for not-regulated ones
Fig. 2 a High-throughput RT-qPCR/RNA-seq correlation over the top-42 DEGs. Simple linear regression (95% confidence interval in grey) was performed for resistant (triangles) and sensitive (circles) subjects, respectively. Pearson correlation is estimated as regression curve slope. Each regression also reports 95% confidence intervals of the estimates (95% CI) and corresponding P-values. b Volcano plot of the HT RT-qPCR data. The plot reports the negative log10 of the Benjamini-Hochberg adjusted P value against the log2 fold-change (resistant vs. sensitive). The significance level for gene regulation is set to 0.05. Each gene is a dot, highlighted in blue for down-regulated genes, red for up-regulated, and grey for not-regulated onesCC BY · PubMed Central
Fig. 3 a Morphology of primary HGSOC cell lines (scale bars 200 μm) and representative images of cytokeratin 7 immunohistochemical and immunofluorescence staining (scale bars 100 and 20 μm). b Waterfall plot for paclitaxel and cisplatin IC50 values (extracted from dose-response curves) of primary and established HGSOC cell lines. The steady state (Css) or the maximum in vivo plasma concentrations are indicated by the solid line (see Table S5). Bars above the solid line represent the resistant samples and bars below represent the sensitive samples. c) Polar bar plot of the 10 selected biomarkers. Ten biomarkers have been chosen from the intersection of the top-42 RNA-seq DEGs with BH-adjusted P-value less than 5E-03 and |log2FC| > 1 and HT RT-qPCR two-sided Wilcoxon rank sum test P value < 0.05. For each of them, the bar colour shading corresponds to the estimated resistant – sensitive shift, and the bar height corresponds to the number of evidences supporting their regulation (1: patients only; 2: patients and OV.GEM cell lines). The black dots show the -log10 of the Wilcoxon’s P-value (the further the distance from the center, the stronger the significance). The red circle corresponds to a P value of 0.05
Fig. 3 a Morphology of primary HGSOC cell lines (scale bars 200 μm) and representative images of cytokeratin 7 immunohistochemical and immunofluorescence staining (scale bars 100 and 20 μm). b Waterfall plot for paclitaxel and cisplatin IC50 values (extracted from dose-response curves) of primary and established HGSOC cell lines. The steady state (Css) or the maximum in vivo plasma concentrations are indicated by the solid line (see Table S5). Bars above the solid line represent the resistant samples and bars below represent the sensitive samples. c) Polar bar plot of the 10 selected biomarkers. Ten biomarkers have been chosen from the intersection of the top-42 RNA-seq DEGs with BH-adjusted P-value less than 5E-03 and |log2FC| > 1 and HT RT-qPCR two-sided Wilcoxon rank sum test P value < 0.05. For each of them, the bar colour shading corresponds to the estimated resistant – sensitive shift, and the bar height corresponds to the number of evidences supporting their regulation (1: patients only; 2: patients and OV.GEM cell lines). The black dots show the -log10 of the Wilcoxon’s P-value (the further the distance from the center, the stronger the significance). The red circle corresponds to a P value of 0.05CC BY · PubMed Central
Fig. 4 Picture showing the potential role of the identified genes in the development of cell-autonomous and non–cell-autonomous resistance to antineoplastic agents, according to literature data. Created with BioRender.com
Fig. 4 Picture showing the potential role of the identified genes in the development of cell-autonomous and non–cell-autonomous resistance to antineoplastic agents, according to literature data. Created with BioRender.comCC BY · PubMed Central

Verification

Claims the paper makes

15 Valid · 2 Not valid · 23 Not checked · 57 Own results and interpretations

37 more claims

Create a free account to see all 97 claims and to verify the 5 references still open.

See all claims — free account
  • Probably not a substantial claim. 48
  • It may state two separate claims as one. 27

Create a free account to see these claims.

Citations

Cites

Show all 74 references

Research works printed but not linked: 3

  1. Leek JT, Johnson WE, Parker HS, Fertig EJ, Jaffe AE, Zhang Y, et al. Sva: surrogate variable analysis. R package version 3.40.0; 2021.
  2. Liaw A, Wiener M. Classification and regression by randomForest. R News. 2002;2:18–22.
  3. Slawski M, Boulesteix A, Bernau C (2021). CMA: synthesis of microarray-based classification. R package version 1.50.0.

Cited by

See all 32

Metadata

Authors
Buttarelli, M., Ciucci, A., Palluzzi, F., Raspaglio, G., Marchetti, C., Perrone, E., Minucci, A., Giacò, L., Fagotti, A., Scambia, G., & Gallo, D.
Affiliations
  • Università Cattolica del Sacro Cuore (IT)
  • Agostino Gemelli University Polyclinic (IT)
Corresponding author
Gallo, Daniela
Venue
Journal of Experimental & Clinical Cancer Research
Published
2022-02-04
Volume
41
Issue
1
Pages
50-50
ISSN
  • 0392-9078 (ISSN-L)
  • 1756-9966
OpenAlex
W4210641711
Cited by
32
References
74
Citations by year
2026: 6 · 2025: 5 · 2024: 9 · 2023: 7 · 2022: 5
FWCI
6.10
Type
journal article
Language
en
Open access
Licence
Locations
  • Journal of Experimental & Clinical Cancer Research (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • PubliCatt (Università Cattolica del Sacro Cuore) (submittedVersion, other-oa)
Topics
  • Health Sciences › Medicine › Oncology › Ovarian cancer diagnosis and treatment
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › BRCA gene mutations in cancer
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
Keywords
high-grade serous ovarian cancer, BRCA wild-type, chemotherapy response prediction, gene expression signatures, platinum-free interval, chemoresistance, predictive biomarkers, immune response, creatine kinase B, PLCγ2, IGFBP7
MeSH terms
Female, Humans, Ovarian Neoplasms, Retrospective Studies, Survival Analysis, BRCA1 Protein, Gene Expression Profiling, Neoplasm Grading

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Identification of a novel gene signature predicting response to first-line chemotherapy in BRCA wild-type high-grade serous ovarian cancer patients. https://app.cochat.ai/papers/10.1186/s13046-022-02265-w
The paper
Buttarelli, M., Ciucci, A., Palluzzi, F., Raspaglio, G., Marchetti, C., Perrone, E., Minucci, A., Giacò, L., Fagotti, A., Scambia, G., & Gallo, D. (2022). Identification of a novel gene signature predicting response to first-line chemotherapy in BRCA wild-type high-grade serous ovarian cancer patients. Journal of Experimental & Clinical Cancer Research. https://doi.org/10.1186/s13046-022-02265-w

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.